Home/Entrada Therapeutics/Dehua Pei

DP

Dehua Pei

Scientific Co-Founder

Entrada Therapeutics

Therapeutic Areas

Neuromuscular Metabolic Retinal

Entrada Therapeutics Pipeline

Drug	Indication	Phase
ENTR-601-44	Duchenne Muscular Dystrophy (Exon 44 skipping)	Phase 1/2b
ENTR-701	Myotonic Dystrophy Type 1	Phase 1
ENTR-601-51	Duchenne Muscular Dystrophy (Exon 51 skipping)	Preclinical
ENTR-601-50	Duchenne Muscular Dystrophy (Exon 50 skipping)	Preclinical

Leadership Team at Entrada Therapeutics

Sweta Girgenrath

Vice President, Therapeutic Research and External Innovation Lead

Michael St. Andre

Principal Scientist

Principal Scientist

View full Entrada Therapeutics profile